FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns application of immediate-release siponimod dosage form in production of drug for treating autoimmune disease. Drug represents a package containing daily doses of immediate-release dosage forms containing 0.25 mg and 2 mg of siponimod, where the amounts refer to siponimod amounts in free form and siponimod is 1-{4-[1-((E)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-ethylbenzyl}azetidine-3-carboxylic acid in free form or in form of a pharmaceutically acceptable salt. Also disclosed is a package and a method of treating a patient with an autoimmune condition.
EFFECT: group of inventions widens the range of products for treating secondary progressive multiple sclerosis.
9 cl, 2 dwg, 10 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IDENTIFICATION OF PATIENTS' REACTION TO ADMINISTRATION OF S1P RECEPTOR MODULATOR | 2013 |
|
RU2785736C2 |
| DOSAGE REGIMEN OF RECEPTOR S1P AGONIST | 2009 |
|
RU2561681C2 |
| DOSING MODE OF S1P RECEPTOR MODULATOR | 2010 |
|
RU2776152C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) | 2017 |
|
RU2721282C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR REMITTENT AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS | 2010 |
|
RU2428693C1 |
| METHOD OF DIABETES TREATMENT | 2007 |
|
RU2442585C2 |
| COMPOSITION COMPRISING HYDROCORTISONE | 2014 |
|
RU2664678C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS IN CHILDREN | 2015 |
|
RU2596792C1 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
| METHOD FOR TREATING EXACERBATIONS IN CASE OF MULTIPLE SCLEROSIS | 2003 |
|
RU2257915C2 |
